Articleposted May 08, 2023
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Hua-Yuan ZHU, Yi Miao, Yeqin Sha, Yi Xia, Shu-Chao Qin, Rui Jiang, Luomengjia Dai, and 10 more authors
Under Revision
at
Articleposted Mar 24, 2023
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia
Paul Hengeveld, Joyce Schilperoord-Vermeulen, Michèle van der Klift, Julie Dubois, P. Kolijn, François Kavelaar, Melissa Rijken, and 7 more authors
Under Revision
at
Articleposted Mar 24, 2023
Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndromes Defined by International Consensus Classification
Wan-Hsuan Lee, Ming-Tao Tsai, Cheng-Hong Tsai, Feng-Ming Tien, ming-yen lo, Mei-Hsuan Tseng, Yuan-Yeh Kuo, and 11 more authors
Under Revision
at
Articleposted Mar 20, 2023
Monitoring of measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation
Jong-Mi Lee, Ari Ahn, Eun Jeong Min, Sung-Eun Lee, Myungshin Kim, Yonggoo Kim
Under Review
at
Articleposted Mar 08, 2023
Primary cells from patients with adult T cell leukemia/lymphoma depend on HTLV-1 Tax expression for NF-kB activation and survival
Rita Hleihel, Hala Skayneh, Hugues de The, Olivier Hermine, Ali Bazarbachi
Published
at
Articleposted Mar 02, 2023
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling
Ignacio Cardona-Benavides, IRENA Misiewicz-Krzeminska, Elizabeta A. Rojas, Cristina de Ramón, Antonio Sanz-Solas, Isabel Isidro, Dalia Quwaider, and 9 more authors
Under Review
at
Articleposted Mar 01, 2023
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first line ibrutinib: a nationwide registry study from the Italian Medicines Agency
Gian Matteo Rigolin, Pier Paolo Olimpieri, Valentina Summa, Simone Celant, Lydia Scarfò, Lucia Tognolo, Maria Pia Ballardini, and 8 more authors
Under Review
at
Articleposted Feb 24, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, and 14 more authors
Under Review
at
Articleposted Feb 10, 2023
Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression
Xin Yan, Zefeng Xu, Peihong Zhang, Qi Sun, Yujiao Jia, Tiejun Qing, Shiqiang Qu, and 10 more authors
Published
at
Articleposted Jan 23, 2023
An atlas of the bone marrow bone proteome in patients with dysproteinemias.
Matthew Ho, Surendra Dasari, Alissa Visram, Matthew Drake, Cristine Charlesworth, Kenneth Johnson, Ganesh Pujari, and 2 more authors
Published
at